Moderna and Merck share positive results for mRNA-4157 plus Keytruda
Shares of US biotech Moderna (Nasdaq: MRNA) surged 9.3% to $85.87 by close on Thursday, after trial results of its Merck & Co (NYSE: MRK) jointly developed experimental cancer vaccine, mRNA-4157, used in conjunction with Merck's Keytruda (pembrolizumab) treatment, showed reduced risk of death or relapse in patients with the most deadly form of skin cancer after three years.
Data from the Phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study showed that, over three years, high-risk melanoma patients receiving both the vaccine and Keytruda saw the risk of recurrence or death cut by 49% compared to patients receiving Keytruda alone, the companies announced.
They also saw a 62% reduction in the chance that the cancer would spread or that they would die when using both treatments, compared to using Keytruda alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze